Bayer announced that the US FDA has approved finerenone, the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist, under the brand name Kerendia®.
[Bayer, Inc.]
Sorry, but the selected Zotpress account can't be found.
Home Newsletters Pancreatic Cell News U.S. FDA Approves Finerenone for the Treatment of Patients with Chronic Kidney...
